Shrunken FDA Advisory Committee Is Unanimous: Leqembi Works
The panel was persuaded of the antibody’s clinical efficacy and overall favorable benefit/risk ratio, although it had questions about risk in certain subgroups.
207 RESULTS
Sort By:
The panel was persuaded of the antibody’s clinical efficacy and overall favorable benefit/risk ratio, although it had questions about risk in certain subgroups.
In VSP35 knockout cells, surface proteins get trapped in endolysosomes. They swell with undigested proteins and APP, then spew their contents outside the cell.
In amyloidosis mice, decline of the hypothalamic melanin-concentrating hormone system jacks up neuronal activity, and contributes to sleep problems.
A tiny PET study saw gliosis in putamen and striatum of some with persistent depression after COVID; larger health registry studies find scant evidence.
Dozens of structural features of the heart correlated with measures of regional volume, integrity of white-matter tracts, and functional connectivity within the brain.
The agency reiterated its earlier decision that traditionally approved amyloid antibodies will be covered if physicians enter data into a patient registry.
Among cognitively healthy people, amyloid load tracked with blood p-tau181 and tangles only in those with high blood GFAP.
Backed up, the cells never transitioned into a disease-associated state, shirking their plaque compaction and synapse protection duties.
Three reviews, two perspectives, and four comments discuss recent advances and opportunities for dementia research.
More evidence that presynaptic tau may spread from neuron to neuron.
Mendelian randomization identified HDL cholesterol and systolic blood pressure as modifiable risk factors.
Arranged in bundles and lattices within a plaque, Aβ42 fibrils were intermixed with extracellular vesicles of different shapes and sizes. Their origin remains unknown.
Transplanting a human cerebral organoid containing microglia into a mouse brain allows the cells to thrive in something close to their natural environment.
Multiplex analyses spy a new microglial subtype that surrounds Aβ plaques, and a type of neuron resilient to neurofibrillary tangles.
They can be neutralized by lecanemab, an anti-amyloid antibody designed to mop up Aβ protofibrils.